EM Imaging appoints new chairman
pharmafile | September 10, 2015 | Appointment | Manufacturing and Production, Research and Development | EM Imaging, Optometry, ophthalmology
The board of Edinburgh Molecular Imaging Ltd (EM Imaging) is pleased to announce the appointment of John Jeans as non-executive chairman.
In an career spanning 35 years, Jeans held senior international leadership positions in global companies including Smith & Nephew, Bristol Myers Squibb, Johnson & Johnson and Amersham plc (now GE Healthcare). He headed the commercial function of GE’s Life Science business and was the chairman of its UK Healthcare Company.
His domain expertise ranges from medical devices and pharmaceuticals to in-vivo and in-vitro diagnostics; encompassing research, product development, manufacturing and commercialisation.
Jeans is chairman of the council of Cardiff University and Imanova. In addition he chairs the board of UK Biocentre, is a non-executive director of Renishaw and a board member of the University and College Employers Association.
An advisor to public and third sector organisations, he was appointed by the Prime Minister in 2014 as the UK Government’s life science champion for medical technology. Jeans leads Innovate UK’s Stratified Medicine Advisory Board and the KTN’s Health Board, and has sat on advisory panels for the MRC, EPSRC, NIHR and the Wellcome Trust.
He has served on several Government bodies including co-chairing a ministerial committee on medical technologies, is an inaugural member of the Science Advisory Council for Wales and a founder trustee of the Francis Crick Institute. He is also chair of the Strategic Advisory Panel for the Singapore Government’s Diagnostics Hub.
Jeans was previously the deputy chief executive of the Medical Research Council, a member of its Audit and Risk Committee and chaired the trustee board of MRC Technology. He was awarded a CBE for services to Life Sciences, Healthcare and Science in 2012.
Commenting on the changes to the board, Ian Wilson, CEO of EMI, says: “I am delighted to welcome John to the board. With his extensive experience in the healthcare and diagnostics sector, John is an extremely valuable addition to the company. His deep expertise and leadership skills will be central to supporting EM Imaging in bringing its novel optical imaging technology to the forefront of the global molecular imaging market.”
Jeans comments: “The team at Edinburgh Molecular Imaging have made great progress in establishing a strong portfolio of optical imaging opportunities and it’s a privilege to be joining the company as it enters this exciting period of further development.” His role came into effect on 31st August 2015.
Related Content
Addenbrooke’s hospital offers first self-service digital eye test
Addenbrooke’s Hospital, Cambridge, has become the first in the UK to deploy a digital self-testing …
Merck to acquire EyeBio for an upfront $1.3bn
Merck, known as MSD outside of the US and Canada, and EyeBiotech Limited, have announced …
Astellas and 4D Molecular Therapeutics enter license agreement for rare ophthalmic targets
Astellas Pharma and 4D Molecular Therapeutics (4DMT) have announced a license agreement under which Astellas …
